Compare FirstEnergy Corp. (FE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Moderna, Inc. — how do they compare? FirstEnergy Corp. trades at $48.93 (market cap $28.13B), while Moderna, Inc. trades at $63.26 (market cap $27.09B). The key difference: FirstEnergy Corp. and Moderna, Inc. are close in size by market cap, and FirstEnergy Corp. pays a 3.82% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| FE | MRNA | |
|---|---|---|
Market Cap | $28.13B | $27.09B |
Sector | Utilities | Health |
52-Week High | $51.91 | $81.80 |
52-Week Low | $40.30 | $22.36 |
Enterprise Value | $56.14B | $23.19B |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy Corp. (FE) trades at $49.17, down 0.1% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue growth is steady at $15.09 billion for 2025. The company benefits from rising data center demand and a $36 billion investment plan, highlighted by recent news of grid upgrades and leadership appointments to drive operational performance.
Outlook is positive with a consensus price target of $52.00, offering ~6% upside. Key opportunities include infrastructure investments and data center growth, but risks involve high debt levels and regulatory pressures. Institutional sentiment is bullish with no sell ratings, though net cash flow remains negative, requiring careful monitoring of capital expenditures.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
